- Home
- Equipment
- usa north carolina
- small molecule targeted drug
Refine by
Small Molecule Targeted Drug Equipment Supplied In Usa North Carolina
5 equipment items found
Manufactured by:Symberix, Inc. based inDurham, NORTH CAROLINA (USA)
Symberix is advancing a portfolio of first-in-class drug candidates for multiple adjunct and monotherapeutic indications. Our discovery platform enables precise targeting of bacteria implicated in intestinal toxicity and gastrointestinal disease. By identifying specific bacterial enzyme targets, we can develop small ...
Manufactured by:ApiJect Systems, Corp. based inStamford, CONNECTICUT (USA)
Blow-Fill-Seal (BFS) is a globally-trusted aseptic packaging technology where the pharmaceutical-grade plastic container is made, filled with the liquid drug product, and sealed in a rapid, continuous process. BFS is used around the world to package billions of doses of both large and small molecule sterile drug products annually, including ...
Manufactured by:Jericho Sciences, LLC based inDurham (RTP), NORTH CAROLINA (USA)
Jericho is developing a new therapeutic drug for FIV infection in cats, working toward a New Animal Drug Application (NADA) with the FDA. Our ongoing studies indicate that Jericho’s small molecule drug candidate can reduce FIV virus levels in chronically-infected cats for many months in the absence of continuing treatment. Extensive testing also indicates that the drug candidate has a good ...
Manufactured by:Symberix, Inc. based inDurham, NORTH CAROLINA (USA)
A microbiome is a collection of microorganisms (and their DNA) that occupy a particular location. The "human microbiome" is composed of trillions of tiny microbes (mostly bacteria) that thrive in our mouth, on our skin, and inside our gut. An individual's gut microbiome is a unique and diverse community of thousands of distinct bacterial species. The vast majority of these bacteria are not ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...